Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Mar 2;16(3):e0247878. doi: 10.1371/journal.pone.0247878

Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia

Biruk Bayleyegn 1,*, Berhanu Woldu 1, Aregawi Yalew 1, Fikir Asrie 1
Editor: Grzegorz Woźniakowski2
PMCID: PMC7924809  PMID: 33651817

Abstract

Background

Isolated or multi lineage cytopenia are the most common clinicopathological features and independently associated with increased risk of disease progression and death among human immunodeficiency virus infected children. In the study area, there is scarcity of data about the magnitude of various cytopenia.

Objectives

Aimed to determine the magnitude and associated factors of peripheral cytopenia among HIV infected children at the University of Gondar Specialized Referral Hospital ART clinic, Northwest Ethiopia.

Methods

Institutional based cross-sectional study was conducted on 255 HIV infected children from January- April 2020. None probable convenient sampling technique was used to select the study participant. Socio demographic data were collected by pre tested structured questionnaire via face-to-face interview and their medical data were obtained from their follow-up medical records. Moreover, blood specimens were collected and examined for complete blood count, viral load and blood film, whereas stool specimens were collected and examined for intestinal parasites. Bi-variable and multi-variable logistic regression models were fitted to identify associated factors of cytopenia. P-Value <0.05 was considered as statistically significant.

Result

The overall magnitude of peripheral cytopenia was 38.9%. Anemia, leukopenia, lymphopenia, thrombocytopenia and bi-cytopenia were 21.2%, 12.2%, 11%, 1.6% and 3.9% respectively. Being in the age group of 2–10 years (AOR = 5.38, 95%CI 2.33–12.46), AZT based regimen (AOR = 5.44, 95%CI: 2.24–13.21), no eating green vegetables (AOR = 2.49, 95% CI: 1.26–4.92) and having plasma viral load >1000 copies /ml (AOR = 5.38, 95%CI: 2.22–13.03) showed significant association with anemia.

Conclusion

Anemia was the predominant peripheral cytopenia among HIV infected children in this study. It was strongly associated with AZT based drug type, age below 10 years and high viral load. Critical stress should be given for early investigation and management of cytopenia in addition to the use of alternative drug which leads to higher viral suppression and lower risk of toxicity issue.

Introduction

Hematological abnormalities are the most common clinicopathological features of human immunodeficiency virus (HIV) infection. Of these hematological abnormalities, peripheral cytopenia is become the most common manifestation, which is a reduction of any of the blood cell lines leading to leukopenia, anemia, and thrombocytopenia in the peripheral blood among patients with HIV infection [1]. In both antiretroviral-treated and untreated individuals, cytopenia is independently associated with an increased risk of disease progression and death [2]. The pathophysiological mechanisms responsible for HIV related cytopenia are quantitative and qualitative marrow defects and immune cytopenia. So far, the reduction of colony forming unit of granulocyte, erythrocyte, monocyte and megakaryocyte (CFU-GEMM) and erythropoietin production by HIV itself and indirectly through HIV proteins such as the envelope protein and abnormal levels of cytokine in the bone marrow (BM), prolonged use of anti-retroviral therapy (ART), opportunistic infection (OI) and malignancies are a key mechanism for HIV associated cytopenia [36]. The incidence and severity of cytopenia in HIV-infected children seem to be dependent on the level of viral replication. Since children are potentially at a higher risk of developing viremia due to weight-based dosing, poor tolerability of drugs and suboptimal adherence [4, 7, 8].

Anemia is the most common peripheral cytopenia in people living with HIV. It affects 12.3% to 90% of HIV-infected children and was a strong associated factor of morbidity and mortality [912]. Although HIV associated anemia is multifactorial, the principal factors are infiltration of the BM by neoplasm or infection, myelo-suppressive medications such as Zidovidine and HIV infection by decreasing the production of endogenous erythropoietin. Moreover, red blood cells (RBC) auto-antibodies and the use of various medications may result the consequence of hemolytic anemia. The severity of anemia also increases with advanced stage of HIV disease, the presence of intestinal parasites, malaria, OI and high level of viremia [1315]. Thrombocytopenia is the second most common hematological abnormality found in children with HIV infection. This frequent disorder occurring in about 30–40% of individuals with HIV infection. Thrombocytopenia may occur in all stages of HIV infection and it was identified as a poor prognostic factor for progression of HIV infection to acquired immunodeficiency syndrome (AIDS) and death. But it may increase in associated with high level of viremia in the plasma, type of highly active anti-retroviral therapy (HAART), effects of OI, malignancies and an alteration of the immune system [1618]. Leukopenia occurs in about one-third of children with untreated HIV infection predominantly due to lymphopenia and neutropenia. Reduction in absolute number of CD4+ T-cell lymphocytes occur as one of the earliest immunologic abnormalities of HIV infection and an important prognostic indicator of risk of developing OI. Like anemia and thrombocytopenia, leukopenia has also been reported as due to adverse effects of HAART [1921]. Generally, peripheral cytopenia such as anemia, leukopenia, and thrombocytopenia in associated with HIV infection and treatment can impair the quality of life of people living with HIV/AIDS, particularly children. For this reason the hemoglobin (Hgb) concentration, white blood cell count (WBC), total lymphocyte count and other hematological parameters have been proposed as alternative markers of the disease, especially for developing countries where financial resources are limited [16, 22, 23]. A number of studies have been conducted on cytopenia mainly anemia and among HIV-infected adults. However, there is a scarcity of data about the magnitude of various peripheral cytopenia of all major blood cell lineage among HIV infected children and there is no enough information to associate with viral load. Therefore, this study was carried out to investigate the magnitude and associated factors of peripheral cytopenia among HIV infected children attending at University of Gondar specialized referral hospital, Northwest Ethiopia.

Materials and methods

Study setting and population

Institutional based cross-sectional study was conducted at University of Gondar Specialized Referral Hospital (UOGSRH) ART clinic from January to April 2020. A total of 255 HIV positive children (2 HAART naive and 253 HAART experienced) who attended the UOGSRH ART clinic during the study period were included consecutively. After getting written consent and assent, study participants were enrolled in to the study if they were aged between 6 months to 15 years old. Meanwhile, HIV positive children who were severely sick due to other medical conditions, such as having confirmed chronic renal failure and liver disease, on radiation therapy and immunosuppressive chemotherapy in the previous 45 days, were excluded from the study due to the fact that these may unambiguously affect the hematological values. In addition, those children on treatment for anemia, neutropenia or thrombocytopenia as well as who had traumatic injury or surgical interventions resulting in blood loss and without a legal guardian or unaccompanied children during the study period were not included in this study.

The sample size was computed using single population proportion formula by considering the following assumptions: from cytopenia the prevalence of anemia was 30.9%, far greater than those with thrombocytopenia and leukopenia [24] with 5% margin of error and 95% confidence level then yielding a sample size of 328. Since the source population was <10,000, finite population correction formula is applied by taking an estimated population of 536 HIV infected children at ART clinic during the study period, and then the final sample size was 203. However, to increase the power of the study and since the available data was more than required, 255 available samples were considered for analysis and were included in this study. None probable convenient sampling technique was applied to recruit study participants who meet the inclusion criteria.

Data collection and laboratory procedures

Socio-demographic and clinical data collection

Socio-demographic characteristics of children (such as age, gender, residence, educational status) and socioeconomic/demographic characteristic of family/caregivers, including (age, gender, family income, family size, occupation, education and life status) were collected using a pre-tested structured questionnaire via a face-to-face interview technique. Moreover, detailed clinical data of the children, such as world health organization (WHO) HIV disease stage, OI, type of HAART and HAART experience and duration of HAART were collected by reviewing the medical record of HIV infected children. Anthropometric measurements (height and weight) were taken using calibrated equipment’s by a trained clinical nurse working at pediatric ART clinic and Z-scores of nutritional indices, such as weight-for-age (WAZ), height-for-age (HAZ), weight for height (WHZ) and BMI-for-age (BMA) were scored using WHO Anthro (for children aged ≤5 years) and Anthro-plus (for children aged >5 years) soft ware’s.

Hematological parameters. After collecting 5ml of venous blood sample in EDTA tube from each study participants, CBC results which include RBC parameters (RBC count, Hgb, mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC) and mean cell volume (MCV)), WBC parameters (WBC count, absolute neutrophil count, neutrophil percentage, lymphocyte count, lymphocyte percentage, mixed count that encompasses eosinophil, basophil and monocyte and mixed cell percentage) and platelet parameter (platelet count and mean platelet volume) were determined using sysmex KX21 hematology analyzer. This was accomplished with in one hours of blood collection by experienced hematologist at University of Gondar referral hospital hematology laboratory.

HIV RNA detection and quantification. HIV viral load was determined directly by advanced molecular technique on blood plasm collected from each study participants using plasma separator gel containing EDTA tubes. TAQMAN® AMPLICOR HIV-1 MONITOR (Roche Molecular Systems) which is an in vitro diagnostic nucleic acid amplification test were for the quantification of HIV-1 RNA in human plasma. Template RNA, primer, dNTPmix, were combined with nuclease-free water in a PCR tube. RNase inhibitor and reverse transcriptase was added to the PCR tube. A master mix (containing buffer, dNTP mix, MgCl2, Taq polymerase and nuclease-free water) was added to each PCR tube. Then GAG specific to HIV1 primer was added. PCR tubes were placed in a thermal cycler for 30 cycles of the amplification program, which included three steps: denaturation, annealing and elongation giving real time viral load in copies/μl. Then, the amount of circulating HIV was measured and reported as HIV RNA copies per milliliter (copies/ml) of plasma by well-trained laboratory technologists.

Parasitological examination. For intestinal parasite examination, 3-5gm fresh stool was collected by standard clean, wide mouthed, leak proof and dry plastic stool cup from each study participant. The stool specimens were transported in screw-capped cups in 10% formalin from a sample reception area to the laboratory. Test tub flotation concentration procedures were done for the detection of protozoan cysts, helminthic ova and larvae in addition to using the direct wet mount. This was based on the principle that flotation solution must have a higher specific gravity than the parasite egg (parasite eggs are 1.05–1.24, while flotation solutions specific gravity > 1.24). Thereby during examination of the solution in the topmost layer will clearly indicate the presence of eggs, but the fecal material and fiber settle at the bottom. Moreover, both thin and thick blood films using 10% Giemsa were examined for the detection and identification of malaria parasites and any quantitative as well as qualitative cell abnormality were reported by experienced hematologist.

Operational definition

Peripheral cytopenia:—is defined as reduction in either of the cellular elements of blood, i.e., RBCs, WBCs or platelets [25]. Unicytopenia: defined as patients with isolated anemia, thrombocytopenia or neutropenia. Bi-cytopenia: Defined as having two of the three lineage cell counts below the levels [26]. Anemia:—was defined as Hgb concentration of less than 11 g/dl for 6–59 months of age, less than 11.5 g/dl for ages 5–11 years, and less than 12 g/dl for ages 12–14 years old children. Mild anemia was defined as follows: Hgb 10.0–10.9 g/dl for children aged 6–59 months, 11.0–11.4 g/dl for children aged 5–11 years and 11.5–11.9 g/dl for children aged 12–15 years. Moderate anemia was defined as Hgb 7.0–9.9 g/dl for children aged 6–59 months and 8–10.9 g/dl for children aged 6–15 years. Severe anemia was also defined as Hgb<7.0 g/dl for children aged 6–59 months and <8.0 g/dl for those aged 6–15 years after altitude adjustment by subtracting 0.8 g/dl since the study area altitude is 2133 as recommended by WHO [27] Anemia is usually classified based on the size of RBCs, as measured by MCV. It can be microcytic if MCV typically less than 80 fl, normocytic 80 to 100 fl, or macrocytic greater than 100 fL. Furthermore, it was defined as hypochromic if MCH was <27 pg [28]. Thrombocytopenia:—Defined as when a platelet count < 150 × 103/mm3, categorized as mild (50,000–149,999 platelets/μl), moderate (20,000–49,999) and severe < 20,000 [17] trombocytopenia. Leukopenia:—defined as WBC count <4000/mm3, lymphopenia: as lymphocyte count <1500/mm3 and neutropenia: NC of <1500/mm3, severity further classified as follows: 750–1500/mm3mild neutropenia, 500–750/mm3moderate neutropenia, <500/mm3severe neutropenia and <250/mm3severe life-threatening neutropenia [24, 29].

Data quality assurance

To assure the quality of data, training was given for data collectors prior to data collection and daily close supervision was made during the data collection period. Before the actual data collection date, the questionnaire was pre-tested on 5% of the sample size at Gondar poly health center ART clinic. Then, necessary modification was done based on its analysis. Blood sample was checked whether they were in the acceptable criteria like; free of hemolysis, no clotting, sufficient volume, correct labeling and collection time. All samples were analyzed in one laboratory (University of Gondar specialized referral hospital Hematology laboratory section) with the same hematology analyzer and the same trained hematologists. The performance of Sysmex KX-21 hematology analyzer was checked by daily initialization background check and by running three levels of hematology controls (Normal, Low and High) by applying the principles of Westgard rules and Levy Jennings chart to control the automated instruments. On the other hand, COBAS® TaqMan® Negative control, HIV-1 Low Positive control and HIV-1 High Positive Control in each test batch were used to evaluate the performance of the COBAS AmpliPrep/COBAS TaqMan HIV-1 test. Moreover, known malaria-positive and negative blood were used to check the quality and performance of the Giemsa staining reagent, as well as stool examination were performed after checked the specific gravity of the salt solution was above 1.25 using Hydrometer once a week. Weight and height measuring equipment’s were calibrated by using known weight and height before starting the data collection. Two readings were obtained for each measurement, and the mean of two anthropometric measurements were calculated and used for the analysis.

Data analysis and interpretation

Data were entered into EPI-info 4.4 and have been checked and cleaned for completeness and consistency. Then the data were transferred to statistical package for social science (SPSS) version 20 for analysis. Descriptive statics like frequencies, percentages and medians with interquartile ranges (IQR) for skewed statistical distributions were used to summarize the data. To assess the distribution of data, Shapiro-Wilk test was done. Bi-variable and multi-variable logistic regression were used to measure the association of cytopenia with risk factors. The Hosmer-Lemeshow goodness-of-fit test was used to assess the fitness of the model. Variables with a p value less than 0.2 in the bi-variable analysis were fitted into the multi-variable binary logistic regression analysis to control the possible effect of confounding. Both crude odds ratio (COR) and adjusted odds ratio (AOR) with the corresponding 95% confidence interval (CI) were calculated to measure the strength of association. Finally, in the multi-variable analysis, variables with p values less than 0.05 was considered as statistically significant.

Ethical consideration

Ethical approval was obtained from Research and Ethics Review Committee of the School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar. Furthermore, support and permission letter were secured from UoGSRH. In addition, following an explanation of the purpose, the benefits and the possible risks of the study, written informed consent was taken from a parent/legal guardian and assent was sought from children before commencement of the study. It was made clear that participation in the study were purely on a voluntarily basis and refusal was possible. To ensure confidentiality of data, study participants were coded by using unique codes, and only authorized persons were accessing the collected data. The study participant’s with abnormal findings were linked to the physicians who are working at the ART clinic for proper patient care.

Results

Socio-demographic and clinical characteristics of study participants

A total of 255 HIV positive children (253 HAART experienced and 2 HAART naïve) were recruited into this study, of which half of them were female 128 (50.2%). The median age of the participants was 13 years with interquartile rang (IQR) (10,14) and majority of the children 189(74.1%) were age between 11–15 years. Based on WHO clinical stage criteria of HIV, most of the study participants 245 (96.1%) were in WHO stage I. About 221 (86.7%) of study participants were under ART treatment for the duration of ≥1 year. According to HAART type, about 106 (41.6%) study participants were taking TDF containing HAART regimen. Nearly half (44%) of the study participants were stunted based on WHO nutritional assessment guidelines. In the current study, only 29 (11.4%) of study participants had history of OI, the commonest being TB infection seen in 16 (6.3%), and pneumonia was seen in 12 (4.7%) followed by fungal infection 1 (0.4). Moreover, from a total 255 HIV infected children who participated in the study, 57 (22.4%) of the children had one or more of the following intestinal parasites (E.hsitoltica, Ascarice lumbricode, Tenia spp, Hook Worm, H.nana, Ascaris and E.histolitica, Ascaris and H.nana, trophozoit of Gardia lambilia and oocyst of cryptosporidium spp). Consequently, in this study 80 (31.4%) of the study participants had viral load ≥1000 copies/ml (> 3log10) (Table 1).

Table 1. Socio-Demographic and clinical characteristics of HIV infected children and their family/ guardian who visited UoGSRH ART clinic, Gondar, Northwest Ethiopia, 2020 (N = 255).

Socio-Demographic characteristics Clinical characteristics
Variables Category Frequency (%) Variables Category Frequency (%)
Gender of children Male 127(49.8) WHO staging I 245(96.1)
Female 128(50.2) II 10(3.9)
Age (years) children ≤5 9(3.5) Viral load Not detected 109(42.7)
6–10 57(22.4) ≤1000copies /ml 66(25.9)
11–15 189(74.1) ≥1000 copies/ml 80(31.4)
Residence Urban 226(88.6) BAZ Wasted 45(17.6)
Rural 29(11.4) Normal 210(82.4)
Educational status of children No formal education 22(8.6) HAZ Stunted 111(43.5)
Primary school 201(78.8) Normal 144(56.5)
Secondary school 32(12.5)
Family income per month ≤ 1000 123(48.2) OIs Yes 29(11.4)
1001–2000 78(30.6) No 226(88.6)
>2000 54(21.2)
Family size. ≤4 183(71.8) Presence of diarrhea Yes 20(8.8)
4–6 56(22) No 235(92.2)
>6 16(16)
Marital status of caregiver Married 139(54.3 HAART experience Naïve 2(0.8)
Single 7(2.7) ≤6months 20(7.8)
Separated 23(9) 6-12month 12(4.7)
Widowed 86(33.7) >12month 221(86.7)
Parental status Both live 143(56.1)
Father live 18(7.1)
Mother live 62(24.3)
Both dead 32(12.5)
Relationship to children Mother 160(62.7) HAART Types AZT Containing 78(30.6)
Father 54(21.2) TDF Containing 106(41.6)
Other care giver * 41(16.1) ABC Containing 71(27.8)
Family occupational status Privately employed 31(12.2) Eating animal products Yes 183(71.8)
Government employed 63(24.7) No 72(28.2)
Merchant 75(29.4)
House wife 65(25.5)
Other 21(8.2)
Family educational status No formal education 86(33.7) Eating dark vegetable yes 179(70.2)
Primary school 84(32.9) no 76(29.8)
Secondary and above 85(33.3)
HIV status of caregiver Positive 215(84.3) Intestinal parasite Yes 57(22.4)
Negative 26(10.2) No 198(77.6)
Not known 14(5.5)

Note:—Other care giver * = Female care giver, Male caregiver, Funded organization.

Abbreviation; AZT = zidovudine,TDF = Tenofovir, ABC = Abacavir.

Magnitude of cytopenia among study participants

The overall magnitude of peripheral cytopenia were 38.8%. The magnitude of isolated anemia, leukopenia, lymphopenia, thrombocytopenia and bi-cytopenia among HIV infected children were 21.2%, 12.2%, 11%, 1.6% and 3.9% respectively (Table 2). Among the bicytopenia cases, almost all had anemia and leukopenia together. Based on severity, from a total of anemic children: 4(7.4%), 21(38.9%) and 29(53.7%) had sever, moderate, and mild anemia, respectively while none of the participants had sever thrombocytopenia and leukopenia.

Table 2. Magnitude of cytopenia in HIV infected children, at UoGSRH, Northwest Ethiopia, 2020 (N = 255).

Cytopenia Frequency(N) Percentage (%)
Anemia Yes 54 21.2
No 201 78.8
Leukopenia Yes 31 12.2
No 224 87.8
Neutropenia Yes 1 0.4
No 254 99.6
Lymphopenia Yes 28 11.0
No 227 89.0
Thrombocytopenia Yes 4 1.6
No 251 98.4
Bi-cytopenia 10 3.9
Uni-cytopenia 89 34.9
Total cytopenia 99 38.8

Hemoglobin value and platelet count were showed negatively correlation with viral load (r = -0.02 and -0.03) respectively. However, a study didn’t find a significant correlation between hematological parameters and viral load (p>0.05) (Table 3).

Table 3. Correlation of selected hematological profile with viral load rate, UGCSRH, ART clinic (N = 255).

Viral load
Hematological value Mean ±SD Pearson Correlation = r Sig
Hgb 12.9± 1.9 -0.02 0.8
RBCx106l 4.4± 1.0 0.09 0.2
WBCx103l 6.5±2.3 0.03 0.7
NEUT 45.8 ± 14.2 0.02 0.8
LYM 40.3 ±13.1 0.02 0.7
PLTx103l 324.3 ±89.3 -0.03 0.6

The type of anemia also assessed in this study. Thus, among the total number of cases, the most common type of anemia was normocytic normochromic anemia (74%) (Fig 1).

Fig 1. Type of Anemia detected based on MCV among HIV infected children at UoGCSRH ART Clinic, North West Ethiopia, 2020.

Fig 1

Furthermore, the higher frequency (41.2%) of anemia was detected among children with high viral load (>1000copies/ml) compared to children with undetected viral load as shown in the (Fig 2) below.

Fig 2. Comparison of the magnitude of peripheral cytopenia with its viral load rate among study participants at UoGCSRH, North west Ethiopia, 2020.

Fig 2

This indicated that highest frequency of cytopenia (anemia, leukopenia, thrombocytopenia and bi-cytopenia) were observed among children with high viremia.

Cytopenia and associated factors

Among the variables analyzed in bivariate analyses, age, gender of children, family income, family occupational status, no eating dark green leafy vegetable, BAZ, HAART category and duration of HAART use, WHO’s HIV/AIDS clinical staging and viral load were associated with anemia at p value 0.2. However, in multi-variable logistic regression analysis, controlling the possible cofounders, age of 2–10 years (AOR = 5.383 95%CI 2.326–12.460), AZT based HAART regimen (AOR = 5.44, 95%CI: 2.24–13.21), not eating dark green leafy vegetable (AOR = 2.49, 95%CI:1.26–4.92) and viral load >1000copies /ml (AOR = 5.38 95%CI: 2.22–13.03) remained significantly associated with anemia among HIV-infected children (Table 4). Furthermore, gender, family income, WHO staging, HAART type, intestinal parasites were associated with leukopenia in bivariate analysis. However, none of these factors showed statistically significant association with leukopenia in multi-variable logistic regression analysis (Table 5).

Table 4. Bi-variable and Multi-variable logistic regression analysis for associated factors of anemia among HIV infected children at UoGSRH, ART Clinic, Gondar, Northwest Ethiopia, 2020 (N = 255).

Variable Category Anemic (%) Non-anemic (%) COR (95% CI) AOR (95% CI)
Gender Male 32(25.2) 95(74.8) 1 1
Female 22(17.2) 106(82.8) 1.62(0.88–2.99) 0.62(0.34–1.13)
Age (years) 2–10 24(36.4) 42(63.6%) 3.03(1.60–5.72) 5.38(2.33–12.46) ***
11–15 30(15.9) 159(84.1) 1 1
Residence Urban 48(21.2) 178(78.8) 1 1
Rural 6(20.7) 23(79.3) 1.03(0.40–2.68)
Family income per month ≤ 100 35(28.5) 88(71.5) 0.73(0.25–2.16)
1000–2000 10(12.8) 68(87.2) (1.66–4.95)
>2000 9(16.7) 45(83.3) 1
Family size ≤ 4 42(23.0) 141(77.0) 1
4–6 11(19.6) 45(80.4) 1.17(0.17–2.54)
≥6 1(6.2) 15(93.8) 4.81(0.72–38.16)
Parental status Both live 30(21) 113(79) 1
Father live 3(16.7) 15(83.3) 1.34(0.36–4.89)
Mother live 14(22.6) 48(77.4) 0.91(0.44–1.87)
Both dead 7(21.9) 25(78.1) 0.95(0.37–2.4)
Family occupational status Private 4(12.9) 27(87.1) 1 1
Government 10(15.9) 53(84.1) 0.79(0.23–2.74) 3.02(0.72–12.70)
Merchant 15(20) 60(80) 0.59(0.18–1.95) 2.67(0.80–8.98)
Housewife 19(29.2) 46(70.8) 0.36(0.11–1.17) 1.97(0.62–5.98)
Others 6(28.6) 15(71.4) 0.37(0.09–1.52) 1.12(0.36–3.48)
Family educational status No 23(26.7) 63(73.3) 0.57(0.17–1.96)
Primary school 20(23.8) 64(76.2) 0.57(0.19–1.77)
Secondary and above 11(12.9) 74(87.1) 1
WHO staging I 49(20) 196(80) 1
II 5(50) 5(50) 0.25(0.07–0.90) 0.28(0.07–1.10)
BAZ Wasted 14(31.1) 31(68.9) 0.53(0.26–1.08) 1.90(0.93–3.91)
Normal 40(19) 170(81) 1 1
HAZ Stunted 27(24.3) 84(75.7) 0.73(0.40–1.33)
Normal 27(18.8) 117(81.2) 1
OIs Yes 8(27.6) 21(72.4) 0.67(0.28–1.61)
No 46(20.9) 180(79.1) 1
HAART Duration
<6months 4(18.2) 18(81.8) 1
6-12month 5(41.7) 7(58.3) 0.31(0.06–1.50) 0.60(0.18–1.99)
>12month 45(20.4) 176(79.6) 0.87(0.28–2.70) 3.05(0.84–11.01)
HAART Type AZT Based 29(38.2) 47(61.8) 0.60(0.24–1.52) 5.32(2.19–12.95) **
TDF Based 17(16) 89(84) 0.88(0.44–1.79) 1.58(0.63–3.94)
ABC Based 8(11) 65(89) 1 1
Eating animal products Yes 35(19.1) 148(80.9) 1
No 19(26.4) 53(73.6) 0.96(0.47–1.95)
Eating green leafy vegetable Yes 29(16.2) 150(83.8) 1
No 25(32.9) 51(67.1) 2.49(1.26–4.92) 2.30(1.09–4.82) *
Intestinal parasite Yes 13(22.8) 44(77.2) 0.78(0.31–1.97)
No 41(20.7) 157(79.3) 1
Viral load <1000 copies /ml 9(13.6) 57(86.4) 1.27(0.50–3.20) 1.27(0.50–3.20)
>1000 copies/ml 33(41.2) 47(58.8) 0.18(0.08–0.37) 5.38(2.22–13.05) ***
Not detected 12(11) 97(89) 1 1

Note: * Refers to statistical significance at P<0.05,

** at P value <0.01 and

*** at P value <0.001.

-COR = crud odd ratio, AOR = adjusted odd ratio, CI = Confidence interval.

Table 5. Leukopenia and associated factors among HIV infected children at UoGSRH, ART Clinic, Gondar, Northwest Ethiopia, 2020 (N = 255).

Variable Category Leukopenia COR 95%CI AOR 95%CI
Yes (%) No (%)
Gender Male 19(15) 108(85) 1 1
Female 12(9.4) 116 (90.6) 0.59(0.27–1.27) 2.27(0.91–5.66)
Age (years) 2–10 9(13.6) 57 (86.4) 1.20(0.52–2.75)
11–15 22(11.6) 167(88.4) 1
Residence Urban 29(12.8) 197(87.2) 1.99(0.45–8.80)
Rural 2(6.9) 27(93.1) 1
Family income per month ≤ 100 15(12.2) 108(87.8) 0.69(0.28–1.70) 1.13(0.33–3.78)
1000–2000 7(9) 71(91) 0.49(0.17–1.42) 1.07(0.30–3.90)
>2000 9(16.7) 45(83.3) 1
Family size ≤ 4 20(10.9) 163(89.1) 1
4–6 8(14.3) 48(85.7) 1.36(0.56–3.28)
≥6 3(18.8) 13(81.2) 1.88(0.49–7.17)
Parental status Both live 19(13.3) 124(86.7) 1
Father live 2(11.1) 16(88.9) 0.82(0.17–3.833)
Mother live 5(8.1) 57(91.9) 0.57(.20–1.61)
Both dead 5(15.6) 27(84.4) 1.21(.42–3.52)
Family occupational status Privately 1(3.2) 30(96.8) 0.32(0.03–3.74)
Government 11(17.5) 52(82.5) 2.01(.41–9.91)
Merchant 10(13.3) 65(86.7) 1.46(1.46–7.25)
Housewife 7(10.8) 58(89.2) 1.15(.22–5.99)
Others 2(9.5) 19(90.5) 1
Family educational status No formal education 11(12.8) 75(87.3) 1.10(.44–2.74)
Primary school 10(11.9) 74(88.1) 1.01(.40–2.58)
Secondary and above 4(11.8) 30(88.2) 1
WHO staging I 28(11.4) 217(88.6)
II 3(30) 7(70) 3.32(.81–13.59) 0.58(0.09–3.88)
BAZ Wasted 4(8.9) 41(91.1) 0.66(.22–1.99)
Normal 27(12.9) 183(87.1) 1
HAZ Stunted 14(12.6) 97(87.4) 1.08(.51–2.29)
Normal 17(11.8) 127(88.2) 1
OIs Yes 5(17.2) 24(82.8) 1.60(0.56–4.56
No 26(11.5) 200(88.5) 1
HAART duration
<6months 2(10) 20(90) 1
6-12month 2(16.7) 10(83.3) 2.00(.24–16.36)
>12month 27(12.2) 194(87.8) 1.39(.31–6.29)
HAART Type AZT Based 16(21.1) 62(78.9) 4.32(1.37–13.64) 3.35(0.96–11.67)
TDF Based 11(10.4) 95(89.6) 1.94(.59–6.35) 1.66(0.42–6.58
ABC Based 4(5.6) 67(94.4) 1
Eating animal products Yes 24(13.1) 159(89.9) 0.71(.29–1.74)
No 7(9.7) 65(90.3) 1
Eating green leafy vegetable yes 22(12.3) 157(87.7) 0.96(0.42–2.19)
No 9(11.8) 67(88.2) 1
Intestinal parasite Yes 11(19.3) 46(80.7) 2.13(0.95–4.76) 2.83(0.08–7.41)
No 20(10.1) 178(89.9) 1
Viral load <1000 copies /ml 8(12.1) 58(87.9) 1.67(0.66–4.23)
>1000 copies/ml 15(18.8) 65(81.2) 0.57(0.21–1.61)
Not detected 8(7.3) 101(93.7) 1

Discussion

Isolated or multi lineage cytopenia due to ineffective hemopoiesis or increased peripheral destruction were the common hematological manifestation among patients with HIV infection. In children with HIV, anemia is the commonest hematological disorder. By itself HIV infection is an obvious cause of most dysfunction, but this is also compounded by opportunistic infections, inflammation, malnutrition and nutritional deficiencies, malignancy and drug toxicity [30].

Anemia and leukopenia especially lymphopenia were common findings in the present study which is in agreement with result documented by different studies [1921, 31, 32]. The most common hematological derangement in the current study was anemia with over all prevalence of 21.2%. This finding is almost comparable with different literatures conducted by Abebe et al in Jimma, Ethiopia, which is 21.9% [33] and Mihiretie et al in Addis Ababa, Ethiopia 22.2% [34]. However, the prevalence of anemia in this study is low as compared to study done in West Bengal, India, 69% [31], Zimbabwe 30.9% [23], Togo 70.9% [35] and Ghana 63% [32]. These observed differences may be due to differences in age variation of the study participants, sample size difference, diagnostic criteria and cutoff value used to define anemia and epedemicity of blood and intestinal parasite. The most interesting possible reason for the decreased prevalence of anemia in this study could be attributed to the goal and adoption of the recent “WHO 90-90-90 test and treat policy” which brings many more HIV infected children initiated early on HAART thereby reducing anemia comorbidity [36].

Study participants with age of below 10 years had 5 times more risk of developing anemia as compared to those children with age of 11–15 years (95%CI = 2.6–42.6). This is in line with different studies conducted in Ethiopia [24, 37]. This higher prevalence of anemia in children could be explained by the accelerated growth and consequent increased requirement for iron during their development in addition to the disease state and immune destruction [38, 39]. However, this result was contradicted with what was reported at Jos, Nigeria, observed that children aged 11–15 years had a significantly lower mean Hgb level as compared to the younger children due to longer duration of HIV infection in this group of children which could have resulted in more severe changes in cytokine production and erythropoietin production [39].

Moreover, this study also revealed that HIV infected children not eating green leafy vegetables were at high risk of developing anemia (AOR = 2.30 95%CI = 1.10–4.82) which is comparable with the study done by Enawgaw et al [40]. This may be due to the fact that dark green leafy vegetables exert the beneficial effects smainly through their high non-heme iron and folic acid content which are contributory cause of anemia [41].

This study also showed that high plasma viral load (viral load > 3log10) was presented in 41.2% of anemic study participants and found to be independently associated with the presence of anemia (AOR = 5.38 95%CI = 2.218–13.047) as compared to their anemic status of the undetected viral load. This could be explained by the fact that an increase in viral activity could be accompanied by a decrease in CFU-GEMM level, reducing production of erythropoietin and increment of apoptosis of erythroid pre-cursors by HIV itself in the children [6]. The result was in agreement with many more literature conducted previously by Ruhinda et al [42], Fenta et al [43], Makubi et al [44] and Shet et al [45]. However, this is not in agreement with a recent study conducted at North Wollo, Ethiopia, which showed no significant difference in the prevalence of anemia [46]. The possible reason encountered to this difference may be due to sample size variation and difference in study design [47].

Furthermore, children on AZT combination HAART regimen was 5 times more risk of developing anemia as compared to those children using other drug regimen (95%CI = 2.2–12.9). The finding in the present study was comparable with the finding reported at Nasarawa State, Nigeria [48], Asia [49] and Logas, Nigeria [50] revealing that more anemic patients on AZT combination than on other treatment regimens. This could be due to AZT has been found to exhibit cytotoxicity to the erythroid precursor cells in the bone marrow [30, 51, 52].

In this study from anemic children 4 (7.4%), 21 (38.9%) and 29 (53.7%) of them had sever, moderate, and mild anemia, respectively. The result was consistent with as 4.5%, 39.4% and 56.1% were severe, moderate and mild anemia reported at Bahir-Dar, Ethiopia [37] and 5%,42.5% and 52.2% were severe, moderate and mild anemia respectively done at Addis Ababa, Ethiopia [34]. However, this is lower than a study conducted at Dares Salaam, Tanzania [44], with a severity of 15%. The possible reason attributed to this difference might be due to that majority of the study subjects in Tanzania were in the WHO clinical stage 3 or 4 and high prevalence of hookworm infestation, which means that parasite causes nutritional competition, RBC destruction and impaired nutrient uptake by a direct damage of the intestinal mucosal wall that leads to sever anemia [53]. But in this study, none of participants had late HIV disease stage and no more intestinal parasite was detected due to anti-helmintic drugs given to all HIV infected children as deworming.

As in several other similar studies, normocytic normochromic anemia was the commonest (74%) of anemia, followed by 18% macrocytic normochromic anemia based on MCV classification. This was nearly in line with study at Hawassa, Southern Ethiopia [43], normocytic normochromic anemia was (64.5%) followed by (19.4%) of macrocytic normochromic anemia. This is also comparable with morphological classification reported in Zimbabwe [23] out of 97 children that the most common anemia were normocytic normochromic anemia (61.5%) and Gondar, Ethiopia [40] 46.5% and 39.5% of normocytic-normochromic and macrocytic-normochromic anemia respectively. The occurrence of more percent of normocytic-normochromic anemia on this study might be due to the greater number of study participants in stage 1 disease. However, macrocytic normochromic was probably due to the effect of ART, particularly AZT, which is responsible for the development of macrocytosis (24) since majority of the participants were on HAART.

The second most common peripheral cytopenia in the current study was leukopenia which accounts 12.2% of study population and was not associated with any associated factors. The possible biological explanation of leukopenia in children with HIV could be a decrease in the number of hematopoietic stem cells (HSCs) in the bone marrow, changes in marrow architecture include decreased cellularity and myelodysplasia as well as decreased levels of the factor that stimulates production of white blood cells in the bone marrow (granulocyte colony-stimulating factor (G-CSF)). Furthermore, HIV infection can directly result in lymphopenia as the infection progresses, leading to a decrease in CD4 lymphocytes (31). The prevalence was found to be nearly similar to the findings in the Kenya study [6] where the rate was found to be 10% and Gondar, Ethiopia [24] which reported 12.0%. But in contradiction to this study, the prevalence was lower than a study done in West Bengal, India 34% [31] and Zimbabwe 46.4% [23]. The reasons for the observed difference might be due to the heterogeneity of study population (small sample size: 100 in India and 97 in Zimbabwe) and stages of HIV infection (none of study participants were in advanced disease stage in the current study). Moreover, in this study lymphopenia was also assessed and seen in 11% of HIV infected children which was in agreement with a study conducted by Amidu N et.al in Ghana [32] found 11%.

Thrombocytopenia was observed in 1.6% of the cases in the current study. The most common reasons being thrombocytopenia was, peripheral destruction of platelets due to cross-reactivity of HIV antibodies, apoptosis of megakaryocytes due to direct HIV infection and abnormal and dysfunctional platelet production [54]. The prevalence was similar with a finding reported by Oshikoya et al [55] found to be 1.4%. However, this is lower than the prevalence 11.4% reported in DASH Lafia, Nigeria [48] and 11% in India [31]. The lower rates of thrombocytopenia in this study could have resulted from almost all of the study participants were on HARRT and none of advanced disease stage was detected. Hence, advanced HIV infection was decreased platelet production due to direct infection of megakaryocytes in bone marrow [47] but HAART to be associated with increased platelet production, markedly reducing HIV related thrombocytopenia [23]. However, none of these independent factors showed statistically significant association with thrombocytopenia, which is similar to a study reported by Melku et al [37]. This is due to very small number of thrombocytopenic children to predict the association between an exposure and the outcome.

Limitation of the study

The main limitation of this study is the single site and cross-sectional nature of its design, which makes relationships between cytopenia and associated factors difficult, as it is temporal association. Other limitation of the study is also that the morphological classification of anemia was not determined. In addition, we didn’t analyze serum ferritin, vitamin B12 and folate levels and bone marrow examination, which potentially limit this study. Another limitation is that no locally established clinical laboratory reference ranges of healthy and HIV-infected children’s in study area, Ethiopia which may lead over or under estimate hematological abnormalities.

Conclusion

The overall magnitude of peripheral cytopenia was 38.9%. Of which, anemia was the predominant cytopenia among HIV infected children. Children below 10 years, those who had high viral load and not eating green leafy vegetables in addition to close monitoring of children on AZT based regimen were more likely to be anemic. Therefore, critical stress should be given for investigation and management of cytopenia in HIV-infected children, particularly for those who are taking AZT based HAART type, those age below 10 years and high viral load. The use of alternative drug which leads to higher viral suppression and lower risk of toxicity issue need to be encouraged. Moreover, large scale and longitudinal studies are recommended in order to strengthen and explore in depth on the cause of cytopenia.

Supporting information

S1 File

(DOCX)

Acknowledgments

First, the authors would like express their deepest gratitude to Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar for allowing them to conduct this research. Authors also would like to thank the entire staff of Hematology Laboratory and pediatric ART clinic nurses working at University of Gondar specialized Referral hospital. Finally, authors would like to thank the study participants and their guardians/family for participating in this study.

Abbreviation

AIDS

Acquired Immunodeficiency Syndrome

BAZ

Body Mass Index for Age Z score

BM

Bone Marrow

EDTA

Ethylene Di amine tetra acetic Acid

HAART

Highly Active Antiretroviral Treatment

HAZ

Height-for-Age Z score

Hgb

Hemoglobin

HIV

Human Immunodeficiency Virus

IQR

Inter Quartile Range

MCH

Mean Cell Hemoglobin

MCHC

Mean Cell Hemoglobin Concentration

MCV

Mean Cell Volume

MPV

Mean Platelet Volume

OI

Opportunistic Infection

RBCs

Red Blood Cells

RDW

Red Cell Distribution Width

UoGSRH

University of Gondar Specialized Referral Hospital

WBCs

White Blood Cells

WHO

World Health Organization

Data Availability

All relevant data are within the manuscript.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Markus G. and Seidel, Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment. Blood, The Journal of the American Society of Hematology, 2014. 124(15): p. 2337 2344. 10.1182/blood-2014-06-583260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kumar M., et al., Hematological abnormalities in early and advanced HIV infectio patients. International journal of scientific study, 2016. 3(11): p. 1–5. 10.17354/ijss/2016/46 [DOI] [Google Scholar]
  • 3.Babadoko A.A., Muktar H.M., and Mamman A.I., Immuno-hematological abnormalities of human immunodeficiency virus-1 infected highly active antiretroviral naive adults in Zaria, Northern Nigeria. Archives of International Surgery, 2015. 5(4): p. 199. [Google Scholar]
  • 4.Thulasi R., et al., Hematological abnormalities in HIV infected individuals in correlation to CD4 counts and ART status. Asian Journal of Medical Sciences, 2016. 7(4): p. 14–18. 10.3126/ajms.v7i4.14033 [DOI] [Google Scholar]
  • 5.Akkina R., New insights into HIV impact on hematopoiesis. Blood, 2013. 122(13): p. 2144–2146. 10.1182/blood-2013-08-518274 [DOI] [PubMed] [Google Scholar]
  • 6.Kibaru E.G., et al., Baseline hematological indices among HIV-1 infected children at Kenyatta National Hospital. Int J Novel Res Healthcare Nursing, 2014. 1(1): p. 21–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Santiago-Rodríguez E., et al., Profile of HIV-infected hispanics with pancytopenia. International journal of environmental research and public health, 2016. 13(1): p. 38. 10.3390/ijerph13010038 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sovershaeva E., et al., Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe. International Journal of Infectious Diseases, 2019. 78: p. 65–71. 10.1016/j.ijid.2018.10.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Alem M., et al., Prevalence of anemia and associated risk factors among adult HIV patients at the anti-retroviral therapy clinic at the University of Gondar Hospital, Gondar, Northwest Ethiopia. J Interdiscipl Histopathol, 2013. 1(3): p. 137–44. 10.4172/scientificreports.662 [DOI] [Google Scholar]
  • 10.Shen Y., et al., Prevalence of anemia among adults with newly diagnosed HIV/AIDS in China. PLoS One, 2013. 8(9): p. e73807. 10.1371/journal.pone.0073807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kibaru E.G., et al., Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy, 2015. 12(1): p. 26. 10.1186/s12981-015-0069-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wagnew F., Eshetie S., Alebel A. et al., Burden of anemia and its association with HAART in HIV infected children in Ethiopia: a systematic review and meta-analysis. BMC Infect 2019. 1032(2019). 10.1186/s12879-019-4656-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Suryana K., et al., Correlations between cluster differentiation 4 counts, human immunodeficiency virus clinical stages, and hemoglobin level among human immunodeficiency virus patients with anemia in Merpati clinic, Wangaya hospital, Denpasar, bali, Indonesia: A cross-secti. Asian Journal of Pharmaceutical and Clinical Research, 2019: p. 426–429. 10.22159/ajpcr.2019.v12i3.30794 [DOI] [Google Scholar]
  • 14.Mengist H.M., Taye B., and Tsegaye A., Intestinal parasitosis in relation to CD4+ T cells levels and anemia among HAART initiated and HAART naive pediatric HIV patients in a model ART center in Addis Ababa, Ethiopia. PloS one, 2015. 10(2): p. e0117715. 10.1371/journal.pone.0117715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Davenport G.C., et al., Hematological predictors of increased severe anemia in Kenyan children coinfected with Plasmodium falciparum and HIV‐1. American journal of hematology, 2010. 85(4): p. 227–233. 10.1002/ajh.21653 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Addis Z., Yitayew G., and Tachebele B., Prevalence of some hematological abnormalities among HIV positive patients on their first visit to a tertiary health institution in ethiopia; a cross sectional study.Int Blood Res Rev, 2014. 2(6): p. 270–8. 10.9734/IBRR/2014/11137 [DOI] [Google Scholar]
  • 17.Nka A.D., et al., Thrombocytopenia according to antiretroviral drug combinations, viremia and CD4 lymphocytes among HIV-infected patients in Cameroon: a snapshot from the City of Yaoundé. BMC research notes, 2019. 12(1): p. 632. 10.1186/s13104-019-4664-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hekİmoğlu C.h., et al., Prevalence and associated factors of thrombocytopenia among human immunodeficiency virus-infected patients at a tertiary care hospital in Izmir, Turkey. Turkish journal of medical sciences, 2017. 47(1): p. 69–75. 10.3906/sag-1510-140 [DOI] [PubMed] [Google Scholar]
  • 19.Mohamad W.M.W., et al., Immunological and Haematological Changes in HIV Infection. Trends in Basic and Therapeutic Options in HIV Infection: Towards a Functional Cure, 2015: p. 105. 10.5772/61259 [DOI] [Google Scholar]
  • 20.Mehta S., Jutur S., and Gautam D., Hematologic manifestations of HIV/AIDS. Medicine Update, 2011. 9: p. 484–90. [Google Scholar]
  • 21.Ako S., et al., Hematological Related Disorders and Transfusion of HIV Patients on Highly Active Antiretroviral Therapy (HAART) in the South West Region of Cameroon: Hematological Monitory Parameters for HIV Follow-Up. J HIV Retrovirus, 2018. 4(1): p. 5. 10.21767/2471-9676.100037 [DOI] [Google Scholar]
  • 22.De Santis G.C., et al., Hematological abnormalities in HIV-infected patients. International Journal of Infectious Diseases, 2011. 15(12): p. e808 e811. 10.1016/j.ijid.2011.08.001 [DOI] [PubMed] [Google Scholar]
  • 23.Madzivire M, C.G., Chikwasha V, Mandisodza A, Haematological features in Paediatric patients on second line Highly Active Antiretroviral Therapy in Zimbabwe. IJRDO—Journal Of Health Sciences And Nursing, 2018. 3(9). [Google Scholar]
  • 24.Geletaw T., et al., Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine, 2017. 8: p. 99. 10.2147/JBM.S137067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Naseem S., et al., Pediatric patients with bicytopenia/pancytopenia: review of etiologies and clinico-hematological profile at a tertiary center. İndian Journal of pathology and microbiology, 2011. 54(1): p. 75. 10.4103/0377-4929.77329 [DOI] [PubMed] [Google Scholar]
  • 26.Fan L., Li C., and Zhao H., Prevalence and Risk Factors of Cytopenia in HIV-Infected Patients before and after the Initiation of HAART. BioMed Research International, 2020. 2020. 10.1155/2020/3132589 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.WHO, Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. 2011, World Health Organization: Geneva. http://www.who.int/vmnis/indicators/haemoglobin. pdf [Google Scholar]
  • 28.Janus J. and Moerschel S.K., Evaluation of anemia in children. American family physician, 2010. 81(12): p. 1462–1471. [PubMed] [Google Scholar]
  • 29.Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 6 ed. 2016: Elsevier Science.
  • 30.Bobat R., HIV Infection in Children and Adolescents. 2020, Switzerland: Springer. 10.1007/978-3-030-35433-6 [DOI] [Google Scholar]
  • 31.Bhowmik A. and Banerjee P., Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak, 2015. 25(2): p. 119–123. [PubMed] [Google Scholar]
  • 32.Quaye W. and Addai-Mensah A., Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. African Health Sciences, 2011. 11(1). . PMCID: PMC3092327 [PMC free article] [PubMed] [Google Scholar]
  • 33.Abebe M. and Alemseged F., Hematologic abormalities among children on Haart, in Jimma university specialized hospital, southwestern ethiopia. Ethiopian Journal of Health Sciences, 2009. 19(2). 10.4314/ejhs.v19i2.69419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mihiretie H., Taye B., and Tsegaye A., Magnitude of anemia and associated factors among pediatric HIV/aids patients attending Zewditu memorial hospital art clinic, Addis Ababa, Ethiopia. Anemia, 2015. 2015. 10.1155/2015/479329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Nambiema A., Robert A., and Yaya I., Prevalence and risk factors of anemia in children aged from 6 to 59 months in Togo: analysis from Togo demographic and health survey data, 2013–2014. BMC public health, 2019. 19(1): p. 215. 10.1186/s12889-019-6547-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.HIV/AIDS, J.U.N.P.o., Ending AIDS: progress towards the 90-90-90 targets: global AIDS update,. 2017, genevia.
  • 37.Tsegay Y.G., et al., Magnitude of cytopenias among HIV-infected children in Bahir Dar, northwest Ethiopia: a comparison of HAART-naïve and HAART-experienced children. HIV/AIDS (Auckland, NZ), 2017. 9: p. 31. 10.2147/HIV.S125958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Gedefaw L., et al., Anemia and risk factors in HAART naive and HAART experienced HIV positive persons in south west Ethiopia: a comparative study. PloS one, 2013. 8(8). 10.1371/journal.pone.0072202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ejeliogu E.U., et al., Zidovudine-Induced Anaemia in Human Immunodeficiency Virus Infected Children on Highly Active Anti-Retroviral Therapy in Jos, Nigeria. Journal of Advances in Medical and Pharmaceutical Sciences, 2014. 1(1): p. 1–10. 10.9734/JAMPS/2014/11241 [DOI] [Google Scholar]
  • 40.Enawgaw B., et al., Prevalence and associated risk factors of anemia among HIV infected children attending Gondar university hospital, Northwest Ethiopia: a cross sectional study. BMC hematology, 2015. 15(1): p. 12. 10.1186/s12878-015-0032-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ghose B. and Yaya S., Fruit and vegetable consumption and anemia among adult non-pregnant women: Ghana Demographic and Health Survey. PeerJ, 2018. 6: p. e4414. 10.7717/peerj.4414 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ruhinda E.N., Bajunirwe F., and Kiwanuka J., Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC pediatrics, 2012. 12(1): p. 170. 10.1186/1471-2431-12-170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Fenta D.A., et al., Anemia and Related Factors Among Highly Active Antiretroviral Therapy Experienced Children in Hawassa Comprehensive Specialized Hospital, Southern Ethiopia: Emphasis on Patient Management. Drug, Healthcare and Patient Safety, 2020. 12: p. 49. 10.2147/DHPS.S230935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Makubi A.N., et al., Risk factors for anaemia among HIV infected children attending care and treatment clinic at Muhimbili National Hospital in Dar es Salaam, Tanzania. Tanzania journal of health research, 2012. 14(1). 10.4314/thrb.v14i1.11 [DOI] [PubMed] [Google Scholar]
  • 45.Shet A., et al., Anemia, diet and therapeutic iron among children living with HIV: a prospective cohort study. BMC pediatrics, 2015. 15(1): p. 164. 10.1186/s12887-015-0484-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Beletew B., et al., Determinants of Anemia among HIV-Positive Children on Highly Active Antiretroviral Therapy Attending Hospitals of North Wollo Zone, Amhara Region, Ethiopia, 2019: A Case-Control Study. Anemia, 2020. 2020: p. 10. 10.1155/2020/3720572 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Angurana S.K. and Angurana R.S., Thrombocytopenia in Pediatric HIV/AIDS. JK Science, 2014. 16(1): p. 4. [Google Scholar]
  • 48.Bello S.O., Audu E.S., and Hassan I., Hematological profile of human immunodeficiency virus-infected children. Sahel Medical Journal, 2020. 23(1): p. 36. [Google Scholar]
  • 49.Bunupuradah T., et al., Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy. International Journal of Infectious Diseases, 2013. 17(10): p. e806–e810. 10.1016/j.ijid.2013.04.006 . PMCID: PMC4074526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Ahumareze R.E., et al., Prevalence of anaemia and the relationship between haemoglobin concentration and CD4 count in HIV positive children on highly active antiretroviral therapy (HAART) in Lagos, Nigeria. Current Pediatric Research, 2016. [Google Scholar]
  • 51.Phe T., et al., Risk factors of treatment-limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment. PLoS One, 2013. 8(3). 10.1371/journal.pone.0060206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Tamir Z., Alemu J., and Tsegaye A., Anemia among HIV infected individuals taking art with and without zidovudine at Addis Ababa, Ethiopia. Ethiopian journal of health sciences, 2018. 28(1): p. 73–82. PMCID: PMC5866291. 10.4314/ejhs.v28i1.9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Getaneh Z., et al., Prevalence of anemia and associated factors among school children in Gondar town public primary schools, northwest Ethiopia: A school-based cross-sectional study. PloS one, 2017. 12(12). 10.1371/journal.pone.0190151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Sandhya A. and Prajapat B., Thrombocytopenia in HIV patients coinfected with tuberculosis. Journal of family medicine and primary care, 2017. 6(4): p. 859. PMCID: PMC5848413. 10.4103/jfmpc.jfmpc_250_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Oshikoya K, Lawal S, Oreagba I, Awodele O, Olayemi S, Iroha E. Adverse events in HIV-infected children on antiretroviral therapy at a teaching hospital in Lagos, Nigeria: a retrospective study. Adv Pharmacoepidem Drug Safety. 2012;1(4):1000117. 10.4172/2167-1052.1000117 [DOI] [Google Scholar]

Decision Letter 0

Jamie Males

14 Jan 2021

PONE-D-20-24807

Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia.

PLOS ONE

Dear Dr. Bayleyegn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please ensure you address each of the methodological concerns raised by the reviewers, and provide the requested details to ensure that your study is fully reproducible.

Please submit your revised manuscript by Feb 26 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Jamie Males

Senior Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

3. You indicated that you had ethical approval for your study. In your Methods section, please ensure you have also stated whether you obtained consent from parents or guardians of the minors included in the study or whether the research ethics committee or IRB specifically waived the need for their consent.

4. In the Methods section, please provide the specific sequences of the PCR primers used in your study.

5. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"First, the authors would like express their deepest gratitude to Department of Hematology and

Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and

Health Sciences, University of Gondar for financial support and allowing them to conduct this

research."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The authors received no specific funding for this work."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://www.omicsonline.org/scientific-reports/JIDT-SR-662.pdf

https://link.springer.com/chapter/10.1007%2F978-3-030-35433-6_10

http://medcraveonline.com/HTIJ/gender-based-differences-in-hematological-and-cd4-t-lymphocyte-counts-among-hiv-patients-in-ido-ekiti.html

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: • Thank you for inviting me to review a manuscript entitled with “Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia”

• Why none probable convenient sampling technique was used to select the

study participant? b/c the result will not be representative

• The sample size is small since the study was conducted solely in a single institution. In addition why not you didn’t take previous proportions which maximize your sample size. Please justify why?

• Why not you didn’t used a case control study to asses factors?

• Ethical clearance: How blood specimens were collected while most children with HIV are anemic, other hematologic complication and malnutrition? Please send the scan of the IRB permission letter

• How did you get each participants since thy may come at different period of follow up period

• Why you select viral load as a main covariate than other independent variables

• It is not recommended to use the term predictors in cross-sectional study please change it with associated factors throughout the paper.

• You run a logistic regression for only 2 outcome variable (anemia and leukopenia) why not you assessed factors of other components of cytopenia?

• Why not you used other logistic regression model when you have more than 1 outcome variable

• The discussion is not in detail, not including other studies done in Ethiopia among HIV positive children.

Reviewer #2: Comments to authors

I am happy by reviewing this manuscript. For improving the quality of the paper, the following comments were forwarded for the authors.

Title: Magnitude and associated factors of peripheral cytopenia among HIV infected children at the University of Gondar Specialized Hospital ART clinic, Northwest Ethiopia.

1. In the abstract, Background section, the author didn’t show the need/argument in the study. In the result section, the factors which affect cytopenia is not stated rather the author depicts merely for anemia. Besides, the conclusion is not in line with the title.

2. In the Methods and materials part, why the author didn’t include the children less than 6 months. it is a critical question

3. In the result part, please re write the way of putting Interquartile range (IQR) with median

4. How can you operationalize the presence or absence of intestinal parasite for this particular study?

5. Be consistent while you write “multivariable versus multivariate analysis”

6. In the result section, you didn’t touch your title because the author operationalized Peripheral cytopenia as a reduction in either of the cellular elements of blood. The author solely done multivariable model for each parameter independently (anemia, and leucopenia)

7. Besides, the author didn’t address the factors which predicts thrombocytopenia

8. In the discussion part, remove unnecessary sentences like “In this study a total of 255 consecutive HIV infected children were evaluated for peripheral cytopenia on their follow up visit at UOGSRH ART clinic.”

9. Correct all the above comments point by point

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Biruk Beletew Abate

Reviewer #2: Yes: Mohammed Ahmed

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Mar 2;16(3):e0247878. doi: 10.1371/journal.pone.0247878.r002

Author response to Decision Letter 0


1 Feb 2021

Response to Reviewers

Dear, Jamie Males (senior Editor):

Thank you for giving the opportunity to submit a revised version of our manuscript titled Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia to journal of Plos One. We grateful to appreciate the time and effort that you and the reviewers have dedicated to providing your valuable feedback on our manuscript. We are grateful to the reviewers for their insightful comments on our paper. We have been able to incorporate changes to reflect most of the suggestions provided by the reviewers. We have provided a point-by-point response explaining how we have addressed each of the editors or reviewers’ comments. We look forward to the outcome of your assessment. Here is a point-by-point manner below.

We hope the revised version is now suitable for publication and look forward to hearing from you in due course.

Yours sincerely,

On behalf of the co-authors

Biruk Bayleyegn

PONE-D-20-24807

Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia. PLOS ONE

Dear Dr. Bayleyegn,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please ensure you address each of the methodological concerns raised by the reviewers, and provide the requested details to ensure that your study is fully reproducible.

Please submit your revised manuscript by Feb 26 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions

see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Authors response: Thanks for your great appreciation and offer.

Journal Requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Authors response: Thank you for raising this point. We agree with your constructive comment and as per your suggestion we re-organized and rewriting in accordance with the journals style throughout the revised version of the manuscript.

2. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Authors response: Thank you for your great looking. We provided the questioners as additional information in both local language and English in the revised manuscript labeled as “S1”.

3. You indicated that you had ethical approval for your study. In your Methods section, please ensure you have also stated whether you obtained consent from parents or guardians of the minors included in the study or whether the research ethics committee or IRB specifically waived the need for their consent.

Authors response: Thank you for your suggestion. It would have been interesting to explore this aspect in the methodological parts of the revised manuscript and it was done as per your comments. This is stated in the methods section of the revised manuscript (at the top of page 6).

4. In the Methods section, please provide the specific sequences of the PCR primers used in your study.

Authors response: You well come. This is an interesting comment. In this study we use specific primers such as “GAG specific to HIV1 primer” in amplification of HIV1 RNA and it was well described in the “methods section, HIV RNA detection and quantification subsection” of the revised manuscript (page 8).

5. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"First, the authors would like express their deepest gratitude to Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar for financial support and allowing them to conduct this research."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The authors received no specific funding for this work."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Authors response: Agreed. This was our typesetting mistake. The University of Gondar only give the chance to do this research rather giving financial support. We remove funding related statement from the revised manuscript and no need of updated funding statement. We correct it in the acknowledgment part of the revised manuscript (page 28)

6. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://www.omicsonline.org/scientific-reports/JIDT-SR-662.pdf

https://link.springer.com/chapter/10.1007%2F978-3-030-35433-6_10

http://medcraveonline.com/HTIJ/gender-based-differences-in-hematological-and-cd4-t-lymphocyte-counts-among-hiv-patients-in-ido-ekiti.html

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

Authors response: Thank you for addressing your constructive comments. Most of the above published articles were used in our paper and cited properly in order to give credit to each article (Reference 30 and Reference 9). This idea taken from these literatures were also rephrase in accordance with our paper and please be confident that no overlapping of the text with any papers.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Authors response: Thank you for your appreciation. This research is done in collaboration with the most senior scientists working at the University of Gondar and by incorporating their comments and suggestion before submitting to the journal. So, we feel that this paper is soundful. ________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

Authors response: Thank you. The statistical part of the manuscript was well performed by statisticians who had well experienced in the field. In this study, the statistician only done statistical analysis for the major cell lineage (anemia and leukopenia) rather neutropenia and lymphopenia in order to limit number of tables. However, we didn’t do statical analysis of one of the three cell lineages “Thrombocytopenia” with independent factors due to that thrombocytopenia was detected among 4 children which is not fulfill the binary logistic regression criteria to predict the association between an exposer and the outcome. ________________________________________3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Authors response: Thank you for your encouragement. We also added the questioners used in this stud as a supplementary information using local language and English version in the revised manuscript.

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Authors response: Thank you. We corrected typographical and grammatical errors throughout the revised version of the manuscript.

________________________________________

5. Review Comments to the Author

Reviewer #1:

• Thank you for inviting me to review a manuscript entitled with “Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia”

• Why none probable convenient sampling technique was used to select the study participant? b/c the result will not be representative

Authors response: Thank you again. In the present study we applied none probable convenient sampling technique to recruited 255 HIV infected children. This was because of that it was impossible to draw random probability sampling techniques due to time and cost considerations. Moreover, as the study also included new HIV infected children it is impossible to use other technique to recruited this child as it is rare case now adays. By this reason we prefer the none probable convenient technique.

• The sample size is small since the study was conducted solely in a single institution. In addition, why not you didn’t take previous proportions which maximize your sample size. Please justify why?

Authors response: We agree with you and thanks for your critical insight. As it was conducted among HIV infected children, there were only 536 HIV infected children during the study period in the Hospital ART registration logbook which was less than 10,000. Then by computing finite population correction formula the total sample size was 203. However, in order to maximize the sample size, we included 255 HIV infected children from 536 which is above the required sample size. In addition, this study was only conducted in a single institution and stated as one of the study limitations, look the limitation part of the revised manuscript (bottom of page 26)

• Why not you didn’t used a case control study to assess factors?

• Authors response: This is an interesting question. Thank you, the reviewer. We agree with you. However, it is difficult to get equal proportion of HAART NAÏVE and HAART experienced children. Now a days new HIV infected child is rare due to Prevention of mother-to-child transmission (PMTCT) programs which offers a range of services for women of reproductive age living with or at risk of HIV to maintain their health and stop their infants from acquiring HIV. Furthermore, in this study only included children between 6 months to 15 years. But according to WHO recommendation the children began HAART immediately after confirmed HIV positive which is impossible to get HAART NAÏVE children who were less than six months. By this reason it is difficult to get HAART naïve children to compare with HAART experienced children in order to assess the independent factors. By this reason we apply cross sectional study design in order to include all HAART naïve and HARRT experienced children.

• Ethical clearance: How blood specimens were collected while most children with HIV are anemic, other hematologic complication and malnutrition? Please send the scan of the IRB permission letter

Authors response: This is an interesting comment. Give you thanks. All study participants who were severely ill were excluded in the study and didn’t give any sample. After explain the purpose and risk of the procedures all voluntary study participants were give their blood sample based on Ethical approval obtained from the ethical and review committee of University of Gondar attached here with.

• How did you get each participant since thy may come at different period of follow up period

Authors response: Thank you for pointing out this. Based on the new WHO recommendation each child have appointing once per month in order to take their ART treatment on the ART clinic and in order to check their health status every month. So, during the 3 months of the study period, all the data collectors and sample collectors were available on the ART clinic and we get each child until the required sample size was obtained. During this study period many more children were contact repeatedly and we only take samples once from each individual.

• Why you select viral load as a main covariate than other independent variables.

Authors response: Good looking. Thank you for your constructive comments. HIV associated hematological abnormalities seem to be dependent on the level of viral replication. These abnormalities are severing among study participants in the late stages of HIV at high viremia and decreased CD4 count. Thus, viral load testing has been viewed as the best predictor of the risk of developing AIDS-related complications and can be used to monitor disease progression; determine prognosis; select patients for therapeutic trials and monitor therapy. This is due to that children are potentially at a higher risk of developing viremia due to weight-based dosing, poor tolerability of drugs and suboptimal adherence. However, CD4+ T cell counts alone seems to be an inadequate immunological parameter to measure prognosis and anti-retroviral therapy. Moreover, in recent WHO’s recommendations, plasma (RNA) viral load is a good marker of therapeutic adherence, disease progression and treatment efficacy as well as the main therapeutic follow-up parameter rather than CD4 counts. By considering this point in this study, viral load determination was the main independent factors of cytopenia among HIV infected children and it was stated shortly at the bottom of the 1st paragraph of the introduction part.

• It is not recommended to use the term predictors in cross-sectional study please change it with associated factors throughout the paper.

Authors response: Thank you for your critical suggestions. We mad it associated factors/independent factors instead of predictors throughout the revised manuscript.

• You run a logistic regression for only 2 outcome variables (anemia and leukopenia) why not you assessed factors of other components of cytopenia?

Authors response: Great looking of this paper. We agree with your constructive comments. However, in this study Thrombocytopenia was detected among 4 children which is unable to perform any association of the dependent and independent variables. In this study we didn’t do statical analysis of one of the three cell lineages “Thrombocytopenia” with independent factors due to that thrombocytopenia was detected among 4 children which is not fulfill the binary logistic regression criteria to predict the association between an exposer and the outcome.

• Why not you used other logistic regression model when you have more than 1 outcome variable

Authors response: Thank you the reviewer for your nice looking. In this study we use binary logistic regression to determine the descriptive value and multi-variable logistic regression to assess the association of dependent and independent variables which is more preferable than other confusing models.

• The discussion is not in detail, not including other studies done in Ethiopia among HIV positive children.

Authors response: Thank you for your suggestion. As much as possible we included the international and local studies to compare the finding of the current study. Notably, in Ethiopia there were no any more studies illustrated about cytopenia among HIV infected children. We have seen puplished studies for appropriateness of our study and most of the studies were reported about only Cytopenia on HAART, or only cytopenia among HAART naïve. But the current study included both HAART Naïve and HAART experienced children which is difficult to compare the current finding with the previous study. So, by considering this point we only included the studies conducted in Ethiopia which stats about magnitude of cytopenia among HIV infected children whether they were HAART naïve or HAART experienced in order to compare with the current finding.

Reviewer #2:

Comments to authors

I am happy by reviewing this manuscript. For improving the quality of the paper, the following comments were forwarded for the authors.

Title: Magnitude and associated factors of peripheral cytopenia among HIV infected children at the University of Gondar Specialized Hospital ART clinic, Northwest Ethiopia.

1. In the abstract, Background section, the author didn’t show the need/argument in the study. In the result section, the factors which affect cytopenia is not stated rather the author depicts merely for anemia. Besides, the conclusion is not in line with the title.

Authors response: Thank you the reviewer for your critical comments. We were agreed with you and corrected as per your comments. In the abstract section we stated the main objective of the study separately from the background section and explained the need of the study. In the result part of this study, the analysis of the association was performed separately with dependent variables such as anemia and leukopenia instead of cytopenia as per the definition of cytopenia is the deficiency of either of the three cell liang in the blood (anemia, leukopenia, thrombocytopenia). So, the major independent factors were associated with anemia rather leukopenia.

2. In the Methods and materials part, why the author didn’t include the children less than 6 months. it is a critical question

Authors response: This is an interesting comment. Thank you again the reviewer. We agree with you. However, children less than 6 month were excluded in the study. This is because of that duration of HAART was one of the independent factors and hence this child taken HARRT less than 6 months were not appropriate to predict whether it is an associated factor or not. In order to conclude duration of HAART is an associated factor of cytopenia the study participants should take treatment not less than 6 months. By this reason children less than six month were not included in this study.

3. In the result part, please re write the way of putting Interquartile range (IQR) with median

Authors response: Thank you. We corrected it in the result section of the revised manuscript.

4. How can you operationalize the presence or absence of intestinal parasite for this particular study?

Authors response: Thank you for raising this point. It is clear that the presence or absence of intestinal parasite means that whether an individual harbor one or more trophozoite/cyst, larvae, or ova of intestinal parasites or not during stool examination. This is stated in the method section, parasitological examination part (bottom of page 8).

5. Be consistent while you write “multivariable versus multivariate analysis”

Authors response: Thank you again. We agree with you and we corrected it throughout the revised manuscript by using multi-variable instead of multivariate.

6. In the result section, you didn’t touch your title because the author operationalized Peripheral cytopenia as a reduction in either of the cellular elements of blood. The author solely done multivariable model for each parameter independently (anemia, and leucopenia)

Authors response: You have raising an interesting point here. As you stated peripheral cytopenia is defined as reduction in either of the cellular elements of blood, i.e., RBCs, WBCs or platelets. Based on this definition if an individual had one cell reduction, he/she was cytopenic and the analysis should perform separately anemia/leukopenia/thrombocytopenia verses independent factors. However, if one study participant had pancytopenia which is defined as reduction of the whole cell lineages, must perform multi-variable analysis of pancytopenia with independent variables. But in this study no pancytopenia was detected, whereas only high magnitude of uni-cytopenia and 10 bi-cytopenic cases were detected. So, based on this multi-variable logistic regression was applied separately such as anemia and leukopenia with independent factors and this is in line with the title.

7. Besides, the author didn’t address the factors which predicts thrombocytopenia

Authors response: Thank you for your critical view. We didn’t do statical analysis of one of the three cell lineages “Thrombocytopenia” with independent factors due to that thrombocytopenia was detected among 4 children which is not fulfill the binary logistic regression criteria to predict the association between an exposer and the outcome.

8. In the discussion part, remove unnecessary sentences like “In this study a total of 255 consecutive HIV infected children were evaluated for peripheral cytopenia on their follow up visit at UOGSRH ART clinic.”

Authors response: Agreed. These like errors were corrected throughout the revised manuscript.

9. Correct all the above comments point by point

Authors response: Thank you all for your constructive comments once again. We have provided a point-by-point response explaining how we have addressed each of the editors or reviewers’ comments above.________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Biruk Beletew Abate

Reviewer #2: Yes: Mohammed Ahmed

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,

https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: 1 Response to Reviewers.docx

Decision Letter 1

Grzegorz Woźniakowski

16 Feb 2021

Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia.

PONE-D-20-24807R1

Dear Dr. Bayleyegn,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Grzegorz Woźniakowski, Full professor, PhD, ScD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Grzegorz Woźniakowski

19 Feb 2021

PONE-D-20-24807R1

Magnitude and associated factors of peripheral cytopenia among HIV-infected children attending at University of Gondar Specialized Referral Hospital, Northwest Ethiopia.

Dear Dr. Bayleyegn:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Grzegorz Woźniakowski

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Attachment

    Submitted filename: 1 Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES